Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on April 23, 2012, regarding events occurring on April 20, 2012. The filing addresses corporate governance changes, specifically the election of a new director and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Annual Cash Fee: $75,000 per year for Dr. Dennis A. Ausiello.
- Expense Reimbursement: Reasonable travel and related expenses for Board and Scientific Advisory Board service.
- Equity Compensation: Currently $0 due to employer policy limitations; future eligibility would adjust the cash fee to $50,000 per year.
Material Changes
The primary material change reported is the election of Dennis A. Ausiello, M.D., as a Class II director on April 20, 2012. His term is set to expire at the annual meeting of stockholders in June 2012. Additionally, Dr. Ausiello will serve as a member of the Company's Scientific Advisory Board (SAB) without additional compensation beyond expense reimbursement.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding the Company's business operations or financial future. No specific risks or contingencies are disclosed in this report, other than the standard note that Dr. Ausiello's compensation structure is subject to change based on his eligibility for equity compensation under his employer's policy.
Investor Verification Checklist
- Verify the terms of the Consulting Agreement (Exhibit 10.1) between the Company and Dr. Ausiello.
- Confirm Dr. Ausiello's current employment status and the specific limitations on compensation imposed by his employer.
- Review the Company's Proxy Statement for details on the standard compensation policy for non-employee directors should Dr. Ausiello become eligible for equity.
- Monitor the upcoming annual meeting of stockholders in June 2012 regarding the expiration of Dr. Ausiello's director term.